<DOC>
	<DOCNO>NCT02274779</DOCNO>
	<brief_summary>There increase number report describe existence proportion prostate cancer patient present reduced number metastasis ( &lt; 5 lesion ) relapse . This oligometastatic status also recognize tumor type melanoma , soft tissue sarcoma , liver , lung , breast cancer , influence management malignancy radical treatment surgical resection employ . Positron Emission Tomography-Computed Tomography ( PET-CT ) study tracer choline acetate reliable tool help diagnosis oligometastatic disease biochemical treatment failure prostate cancer . An aggressive treatment combine androgen deprive therapy ( ADT ) high-dose irradiation oligometastatic lesion , detect PET-CT , may propose oligometastatic patient . Such treatment strategy may hypothetically succeed prolong failure-free interval two consecutive ADT course , even cure select patient limited metastatic burden . In study investigator plan assess biochemical clinical relapse-free survival 2 year prostate cancer 1-5 oligometastases treat concomitantly high-dose conformal Radiation Therapy LH-RH agonist .</brief_summary>
	<brief_title>Salvage Radiotherapy Combined With Hormonotherapy Oligometastatic Pelvic Node Relapses Prostate Cancer</brief_title>
	<detailed_description>1 . Hormonotherapy Hormone therapy recommend Eligard 45 mg act 6 month . It ideally administer day start radiation therapy within 3 month first day radiotherapy . Nevertheless , free prescription leave investigator . When use hormonal strategy ( anti-androgen agonist , LHRH antagonists LHRH ) , administration six month critical . 2 . Radiotherapy Conformational Radiotherapy techniques Intensity-Modulated ( IMRT ) 2.1 ) Doses prescribe - PTV1 PTV5 66 Gy 30 fraction 2.2 Gy - PTV Pelvis : 54 Gy 30 fraction 1.8 Gy - PTV Loge 60 Gy 30 fraction 2 Gy 6 Gy A complement 3 two additional fraction Gy may deliver across lodge PTV . - PTV Relapse Lodge : In addition treat PTV Lodge , additional radiation 6 Gy 3 fraction 2 Gy may make bring total dose 72 Gy 36 fraction 2 Gy . 2.2 ) Treatment Radiation Guided picture ( IGRT ) perform daily . This daily recalibration base least bone structure . It possible readjust nodal structure .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Leuprolide</mesh_term>
	<criteria>1 . Histologically proven adenocarcinoma prostate 2 . Patients age 18 year 3 . PS 01 4 . Previous radical treatment prostate ( radiotherapy surgery ) 5 . PSA increase least 3 assay laboratory last 12 month . 6 . 15 pelvic lymph node metastasis detect 18FCHPET . A relapse dress prostatectomy associate possible . 7 . Upper limit lymph node metastasis : aortic bifurcation 8 . Respect dosimetric constraint organ risk 9 . Treatment hormone therapy may start inclusion , maximum three month prior Day 1 radiotherapy . This hormone necessarily precede free interval treatment least 6 month since last injection , add duration action predictable injection ( 1 , 3 6 month ) 10 . Patient affiliate social security scheme 11 . Patient Information write informed consent form sign 1. bone visceral metastatic relapse associate 2. paraaortic nodal relapse ( upper limit tolerate aortic bifurcation ) 3. 5 lymph node metastases 4 . Proof metastases initial diagnosis 5 . Evidence distant metastasis pelvic lymph node outside prostate bed 6. prior pelvic lymph node Irradiation . Irradiation bed prostate exclusion criterion , junction prior irradiation bed prostatectomy radiation field pelvic lymph node examine carefully 7. castration resistance define clinical biochemical progression despite combined androgen blockade 8. know contraindication pelvic irradiation ( eg , chronic inflammatory bowel disease , ... ) 9. know contraindication hormone therapy , accord standard recommendation force 10. serious Hypertension control appropriate treatment 11 . Other concomitant cancer history cancer ( within 5 year prior study entry ) , except basal cell squamous cell carcinoma skin . 12 . Patient psychological , familial , sociological geographical potentially hamper compliance study protocol followup schedule 13 . Patient already include another interventional study involve approval CPP screening study OLIGOPELVIS 14 . Private person liberty major trust</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Prostate Cancer , Oligometastasis , Radiotherapy , Hormonotherapy</keyword>
</DOC>